HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure

Hageman factor (FXII) is an essential component in the intrinsic coagulation cascade and a therapeutic target for the prophylactic treatment of hereditary angioedema (HAE). CSL312 (garadacimab) is a novel high-affinity human antibody capable of blocking activated FXII activity that is currently unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Ow, Saw Yen, Kapp, Eugene A., Tomasetig, Vesna, Zalewski, Anton, Simmonds, Jason, Panousis, Con, Wilson, Michael J., Nash, Andrew D., Pelzing, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839371/
https://www.ncbi.nlm.nih.gov/pubmed/36628468
http://dx.doi.org/10.1080/19420862.2022.2163459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839371/
https://www.ncbi.nlm.nih.gov/pubmed/36628468
http://dx.doi.org/10.1080/19420862.2022.2163459

Ejemplares similares